Efficacy of low dose, short course prednisolone regimen for relapse of steroid sensitive nephrotic syndrome in children: A multicenter, randomized, placebo-controlled trial

Pankaj Hari0 个研究点目标入组 0 人开始时间: 待定最近更新: 2023年2月6日

研究概览

暂无简介。

•1.Patients with steroid sensitive nephrotic syndrome with at least one relapse in the preceding 12 months, apart from current relapse
•2. Age between 2 and 18 years
•3. In relapse when enrolled, presenting within 3 days of starting therapy
•4. Parents willing to give informed written consent

•1.Current or past history of steroid resistant nephrotic syndrome
•2.Three or more relapses in the last 12 months
•3. Current relapse on alternate day steroids
•4. Therapy with oral or intravenous cyclophosphamide in the preceding 6 months or intravenous rituximab in the preceding 12 months
•5. Immunosuppression plan likely to be changed in the next 12 months
•6. Presentation with life-threatening infection (e.g., cellulitis, peritonitis, pneumonia) requiring hospital admission
•7. Secondary nephrotic syndrome (e.g., lupus erythematosus, IgA nephropathy, amyloidosis)
•8. Known chronic infection (tuberculosis, HIV, hepatitis B or C)
•9. Known malignancy
•10. Estimated glomerular filtration rate <60 ml/min/1.73 m2
•11. Residing more than 100 km away or unwilling to come for regular follow-up

发起方

Pankaj Hari